249 related articles for article (PubMed ID: 23977973)
21. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
Rubinstein A; Pichon-Riviere A; Augustovski F
Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
[TBL] [Abstract][Full Text] [Related]
22. A determination of topics for health technology assessment in Thailand: making decision makers involved.
Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
[TBL] [Abstract][Full Text] [Related]
23. Application of HTA research on policy decision-making.
Youngkong S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
[TBL] [Abstract][Full Text] [Related]
24. A regulatory governance perspective on health technology assessment (HTA) in France: the contextual mediation of common functional pressures.
Barron AJ; Klinger C; Shah SM; Wright JS
Health Policy; 2015 Feb; 119(2):137-46. PubMed ID: 25458970
[TBL] [Abstract][Full Text] [Related]
25. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy.
Ahmed S; Berzon RA; Revicki DA; Lenderking WR; Moinpour CM; Basch E; Reeve BB; Wu AW;
Med Care; 2012 Dec; 50(12):1060-70. PubMed ID: 22922434
[TBL] [Abstract][Full Text] [Related]
26. Looking at CER from the pharmaceutical industry perspective.
Dubois RW
J Manag Care Pharm; 2012 May; 18(4 Suppl A):S9-12. PubMed ID: 22578212
[TBL] [Abstract][Full Text] [Related]
27. Reflections on the evolution of health technology assessment in Europe.
Sorenson C; Chalkidou K
Health Econ Policy Law; 2012 Jan; 7(1):25-45. PubMed ID: 22221927
[TBL] [Abstract][Full Text] [Related]
28. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
[TBL] [Abstract][Full Text] [Related]
29. Health technology assessment, value-based decision making, and innovation.
Henshall C; Schuller T;
Int J Technol Assess Health Care; 2013 Oct; 29(4):353-9. PubMed ID: 23845404
[TBL] [Abstract][Full Text] [Related]
30. Public health policy decisions on medical innovations: what role can early economic evaluation play?
Hartz S; John J
Health Policy; 2009 Feb; 89(2):184-92. PubMed ID: 18619704
[TBL] [Abstract][Full Text] [Related]
31. Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes.
Frønsdal KB; Facey K; Klemp M; Norderhaug IN; Mørland B; Røttingen JA
Int J Technol Assess Health Care; 2010 Jul; 26(3):309-16. PubMed ID: 20584360
[TBL] [Abstract][Full Text] [Related]
32. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
Haas M; Hall J; Viney R; Gallego G
Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
[TBL] [Abstract][Full Text] [Related]
33. When Does FDAMA Section 114 Apply? Ten Case Studies.
Neumann PJ; Saret CJ
Value Health; 2015 Jul; 18(5):682-9. PubMed ID: 26297097
[TBL] [Abstract][Full Text] [Related]
34. Policy making and roles of health technology assessment.
Tantivess S
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S88-99. PubMed ID: 19253491
[TBL] [Abstract][Full Text] [Related]
35. History of health technology assessment in Belgium.
Cleemput I; Van Wilder P
Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():82-7. PubMed ID: 19500438
[TBL] [Abstract][Full Text] [Related]
36. Health care reform and the pharmaceutical industry.
Mossinghoff GJ
Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
[TBL] [Abstract][Full Text] [Related]
37. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
38. Role of technology assessment in health benefits coverage for medical devices.
Braslow NM; Shatin D; McCarthy DB; Newcomer LN
Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
[TBL] [Abstract][Full Text] [Related]
39. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
[TBL] [Abstract][Full Text] [Related]
40. History of health technology assessment: Spain.
Sampietro-Colom L; Asua J; Briones E; Gol J;
Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():163-73. PubMed ID: 19538814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
